The Pharmacy Times® Gastrointestinal Cancer Resource Center is a comprehensive resource for clinical news and expert insights on cancers that occur in digestive tract organs, such as the stomach, large and small intestine, pancreas, colon, liver, rectum, anus, and biliary system.
April 23rd 2024
This approval makes lutetium Lu177 the first therapy to be approved for the treatment of gastroenteropancreatic neuroendocrine tumors in pediatric patients.
Background and Key Concepts in Biosimilars: Improving Awareness and Addressing Common Concerns
1.0 Credit / Law
View More
Clinical Conversations With the Cancer Care Team: Striving for Equitable Access to Oral Anticancer Medications
1.5 Credits / Law, Oncology
View More
Child Abuse: Responsibilities and Protection of the Reporter
1.0 Credit / Law
View More
Early Experience Using Intravesical Gene Therapy for NMIBC: Perspectives from Urinary Oncologists
February 27th 2024For more than 30 years, there has been little treatment advancement for NMIBC patients. Fortunately, a new development in the treatment of NMIBC has been approved by the FDA and is now available.
Read More
No Difference Observed Between Branded, Biosimilar Enoxaparin for Post-Operative Thrombosis
January 4th 2024There was no statistically significant difference between Lovenox (Sanofi–Aventis Pharmaceuticals, France) and biosimilar enoxaparin in the occurrence of post-operative thrombosis for digestive cancer.
Read More
Domvanalimab-Containing Regimen Shows Positive Preliminary Data for Upper Gastrointestinal Cancers
November 9th 2023Domvanalimab plus zimberelimab with chemotherapy demonstrated a positive overall response rate and 6-month progression free survival rate for patients with upper gastrointestinal cancers.
Read More
Trial Results Demonstrate Significant Overall Survival With Zanidatamab in Adenocarcinoma
January 25th 2023In patients with HER2-expressing metastatic gastroesophageal adenocarcinoma administered zanidatamab, the median duration of response was 20.4 months, with a median progression-free survival of 12.5 months.
Read More
Study: Ripretinib BID Well-Tolerated With Similar Safety Profile to Ripretinib QD in GIST
June 23rd 2021Primary results from the randomized portion of the INVICTUS study had previously shown that ripretinib was able to significantly improve progression-free survival with a clinically meaningful overall survival benefit in patients with advanced gastrointestinal stromal tumor.
Read More
Three Major Studies Alter the Practice of Treating Gastroesophageal Carcinomas
April 12th 2021A presentation at the Community Oncology Alliance 2021 Virtual Conference focused on the latest developments in gastrointestinal oncology and how the field of gastroesophageal cancer is responding to 3 major, practice-changing trials.
Read More